tyrosine has been researched along with lenvatinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Salama, ZT; Scott, LJ; Syed, YY | 1 |
| Arasawa, S; Eso, Y; Iguchi, E; Mishima, M; Nakano, S; Seno, H; Takahashi, K; Takai, A; Takeda, H | 1 |
| Amani, AM; Dehaen, W; Ramezanpour, S; Shiri, P | 1 |
| Chen, Y; Dong, Q; Fu, Y; Hu, B; Li, J; Li, TE; Qin, LX; Qin, W; Ren, X; Shen, X; Su, Y; Sun, H; Wang, CQ; Wang, S; Wang, X; Wang, Z; Zhang, Z; Zheng, Y; Zhu, L; Zou, T | 1 |
2 review(s) available for tyrosine and lenvatinib
| Article | Year |
|---|---|
Lenvatinib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Treatment Outcome; Tyrosine | 2019 |
A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy.
Topics: Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Tyrosine | 2022 |
2 other study(ies) available for tyrosine and lenvatinib
| Article | Year |
|---|---|
Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
Topics: Amino Acids, Branched-Chain; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Tyrosine | 2020 |
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; STAT3 Transcription Factor; Tyrosine | 2022 |